First Horizon expands sales force
First Horizon Pharmaceutical Corp. announced that it is expanding its sales force to provide the opportunity for coverage in excess of 70% of the nation.
Roswell, GA-based First Horizon Pharmaceutical Corp. announced that it is expanding its sales force to provide the opportunity for coverage in excess of 70% of the nation, including all major metropolitan service areas.
"This expansion gives us the opportunity to leverage growth of our key products - Nitrolingual® Pumpspray, Robinul,® Ponstel® and Tanafed® - with the largest percentage of coverage First Horizon has enjoyed to date," said Mike Leone, national sales director of Horizon. "I am excited to be a part of the new opportunities we now have as a result of this expansion."
ZS Associates, a Chicago-based organization specializing in pharmaceutical industry territory alignment and targeting, assisted with the expansion effort, creating territories and districts to match Horizon's products and physician specialty targets. The alignment gives First Horizon an increased representative and management presence, bringing its sales and marketing head count to 150 while also allowing for future expansion. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
